CD8A and glioblastoma: Targeting Tregs facilitates tertiary lymphoid structure (TLS) formation, boosts CD4+ and CD8+ T cell function, and enhances the efficacy of radio-immunotherapy, highlighting a key mechanism of resistance and a potential therapeutic target in glioblastoma (van Hooren et al., 2023).